Christopher S Hackett
Overview
Explore the profile of Christopher S Hackett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hackett C, Hirschhorn D, Tang M, Purdon T, Marouf Y, Piersigilli A, et al.
Mol Ther Oncol
. 2024 Sep;
32(3):200862.
PMID: 39308793
Despite therapeutic efficacy observed with immune checkpoint blockade in advanced melanoma, many tumors do not respond to treatment, representing a need for new therapies. Here, we have generated chimeric antigen...
2.
Yi F, Cohen T, Zimmerman N, Dundar F, Zumbo P, Eltilib R, et al.
bioRxiv
. 2024 Mar;
PMID: 38464085
Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS...
3.
Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner E, Scherzer M, et al.
Cancer Res
. 2022 Sep;
82(22):4261-4273.
PMID: 36112789
Significance: Loss of RBMS3 cooperates with BRAFV600E to induce lung tumorigenesis, providing a deeper understanding of the molecular mechanisms underlying mutant BRAF-driven lung cancer and potential strategies to more effectively...
4.
Hossian A, Hackett C, Brentjens R, Rafiq S
Mol Ther
. 2022 Feb;
30(4):1381-1395.
PMID: 35151842
T cells genetically engineered to recognize and eliminate tumor cells through synthetic chimeric antigen receptors (CARs) have demonstrated remarkable clinical efficacy against B cell leukemia over the past decade. This...
5.
Rafiq S, Hackett C, Brentjens R
Nat Rev Clin Oncol
. 2019 Dec;
17(3):147-167.
PMID: 31848460
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven - and impressive - therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with...
6.
Chen J, Hackett C, Zhang S, Song Y, Bell R, Molinaro A, et al.
Cancer Discov
. 2015 Feb;
5(4):380-95.
PMID: 25637275
Unlabelled: Regulation of mRNA splicing, a critical and tightly regulated cellular function, underlies the majority of proteomic diversity and is frequently disrupted in disease. Using an integrative genomics approach, we...
7.
Hackett C, Quigley D, Wong R, Chen J, Cheng C, Song Y, et al.
Cell Rep
. 2014 Dec;
9(3):1034-46.
PMID: 25437558
The development of targeted therapeutics for neuroblastoma, the third most common tumor in children, has been limited by a poor understanding of growth signaling mechanisms unique to the peripheral nerve...
8.
Diede S, Yao Z, Keyes C, Tyler A, Dey J, Hackett C, et al.
Epigenetics
. 2013 Oct;
8(12):1254-60.
PMID: 24107773
Genetic and epigenetic alterations are essential for the initiation and progression of human cancer. We previously reported that primary human medulloblastomas showed extensive cancer-specific CpG island DNA hypermethylation in critical...
9.
Huang X, Dubuc A, Hashizume R, Berg J, He Y, Wang J, et al.
Genes Dev
. 2012 Aug;
26(16):1780-96.
PMID: 22855790
Medulloblastoma (MB) is the most common pediatric CNS malignancy. We identify EAG2 as an overexpressed potassium channel in MBs across different molecular and histological subgroups. EAG2 knockdown not only impairs...
10.
Swartling F, Savov V, Persson A, Chen J, Hackett C, Northcott P, et al.
Cancer Cell
. 2012 May;
21(5):601-613.
PMID: 22624711
The proto-oncogene MYCN is mis-expressed in various types of human brain tumors. To clarify how developmental and regional differences influence transformation, we transduced wild-type or mutationally stabilized murine N-myc(T58A) into...